Scholar Rock Holding Corporation (SRRK) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es David L. Hallal.
SRRK tiene fecha de IPO 2018-05-25, 128 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.67B.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering and developing medicines that target protein growth factor signaling pathways to treat serious diseases. The company's lead candidate, Apitegromab, a myostatin activation inhibitor, has completed Phase 3 clinical trials for spinal muscular atrophy treatment, while SRK-181 is in Phase 1 development for checkpoint inhibitor-resistant cancers. Scholar Rock maintains a strategic collaboration with Gilead Sciences to develop transforming growth factor beta inhibitors for fibrotic diseases, with a broader pipeline addressing neuromuscular disorders, oncology, and fibrosis indications. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company aims to transform patient outcomes across multiple serious disease areas through its targeted therapeutic approach.
